Plasma Markers of Hypercoagulability in Patients with Serious Infections and Risk of Septic Shock

Abstract

Hyperthrombinogenesis due to bacterial septicemia may aggravate the risk of irreversible septic shock. In 22 patients with septicemia complicating urinary or alimentary infections, daily assessment of hemostasis was performed throughout 1 week. Standard screening of hemostasis revealed significantly increased mean values of prothrombin time, fibrinogen, and fibrinogen degradation product (FDP) concentration. However, platelet counts, activated partial thromboplastin times (APTI), thrombin times, ethanol gelation tests, and antithrombin activity remained within the normal range. By contrast, except for insignificant changes in protein C activity and activated factor VII content, specific markers of plasma hypercoagulability, that is, thrombin-antithrombin (TAT) complexes, prothrombin activating factor F 1+2, activated factor XII (XIIa), and dimer D were all markedly increased. Pathologic levels of TAT and XIIa were found in 82% and 73% of all plasma samples, respectively. The augmentation of TAT correlated with prolongation of thrombin time and increases in F 1+2 levels. The increase in XIIa correlated with thrombocytopenia, prolongation of APTr, exhaustion of antithrombin, and accumulation of F 1+2 and FDP in the plasma. Moreover, a significant increase in XIIa, stronger positivity of the ethanol gelation test, a greater increase in FDP, and a more pronounced decrease in protein C activity were observed in 8 patients with fatal septic shock. This study suggests the usefulness of TAT and XIIa measurements in the early recognition of plasma hypercoagulation in serious infections.

Keywords

Bacterial septicemia Thrombin-antithrombin complexes Factor XIIa.

References

1. Gando S , Kameue T , Nanzaki S , et al. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996;75:224-224.

2. ten Cate JW , van der Poll T , Levi M , et al. Cytokines: Triggers of clinical thrombotic disease. Thromb Haemost 1997;78:415-415.

3. ten Cate H , Timmerman JJ , Levi M. The pathophysiology of disseminated intravascular coagulation. Thromb Haemost 1999;82:713-713.

4. Waage A , Brandtzaeg P , Halstensen A. The complex patterns of cytokines in serum from patients with meningococcal septic shock: Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989;169:333-333.

5. Kalter ES , Daha MR , Verhoef J , et al. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 1985;151:1019-1019.

6. Wuillemin WA , Fijnvandraat K , Derkx BHF , et al. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemost 1996;74: 1436-1436.

7. Muller-Berghaus G , ten Cate H , Levi M. Disseminated intravascular coagulation: Clinical spectrum and established as well as new diagnostic approaches. Thromb Haemost 1999;82:706-706.

8. Levi M , de Jonge E , van der Poll T , et al. Disseminated intravascular coagulation. Thromb Haemost 1999;82:695-695.

9. Bick RL . Disseminated intravascular coagulation: Pathophysiological mechanisms and manifestations. Sem Thromb Hemostas 1998;24:3-3.

10.

10. Downey C , Kazmi R , Toh CH. Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis. Thromb Haemost 1998;80:65-65.

11.

11. Gando S , Nanzaki S , Sasaki S , et al. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost 1998; 79: 1111-1111.

12.

12. Bone RC , Sibbald WJ , Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992;101:1481-1481.

13.

13. Swain W. Fibrinogen assay. Clin Chem 1967;13:1026-1026.

14.

14. Wada H , Wakita Y , Nakase T , et al. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1996;51:255-255.

15.

15. Bone R. Sepsis and multiple organ failure: Consensus and controversy. In: Lamy M , Thijs LG (eds). Mediators of Sepsis. Springer-Verlag, New York, 1992:3-3.

16.

16. Maruyama I : Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999;82:718-718.

17.

17. Zeerleder S , Caliezi C , Redondo M , et al. Activation of plasma cascade systems in sepsis: Role of Cl inhibitors. Schweiz Med Wochenschr 1999; 129: 1410-1410.

18.

18. Mesters RM , Mannucci PM , Coppola R , et al. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996;88:881-881.

19.

19. Taylor FB Jr , Chang A , Ruf W , et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991;33:127-127.

20.

20. Colman R. Biologic activities of the contact factors in vivo. Thromb Haemost 1999;82:1568-1568.

21.

21. Pixley RA , De La Cadena RA , Page JD , et al. The contact system contributes to hypotension but not dissemirr2rted intravascular coagulation in lethal bacteremia: In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993;91:61-61.

22.

22. Saetre T , Lindgaard AK , Lyberg T. Systemic activation of coagulation and fibrinolysis in a porcine model of serogroup A streptococcal shock. Blood Coagul Fibrinol 2000;11:433-433.

23.

23. Raaphorst J , Johan Groeneveld AB , Bossink AW , et al. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 2001;86:543-543.

24.

24. Jansen PM , Pixley RA , Brouwer M , et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996;87:2337-2337.

25.

25. Nuijens JH , Huijbregts CC , Eerenberg Belmer AJ , et al. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-C1(-)-inhibitor complexes in sepsis. Blood 1988; 72:1841-1841.

26.

26. De La Cadena RA , Laskin KJ , Pixley RA , et al. Role of kallikrein-kinin system in pathogenesis of bacterial cell wall-induced inflammation. Am J Physiol 1991;260:G213-G213.